A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm

This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cervical Dystonia Blepharospasm Dyskinesias Dystonia Eye Diseases Eyelid Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Torticollis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Bergen, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
treatment with Xeomin® and BOTOX® for at least 1 year each

Exclusion criteria

having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm

Treatment and study plan

No intervention

Other

No treatment (intervention) was administered.

Primary outcomes

Dose of Botulinum Toxin Used to Treat Cervical Dystonia

Time frame: 2 Years

The average dose of botulinum toxin received per patient per year was calculated.
Dose of Botulinum Toxin Used to Treat Blepharospasm

Time frame: 2 Years

The average dose of botulinum toxin received per patient per year was calculated.

Secondary outcomes

Number of Participants With Adverse Events

Time frame: 2 Years

An Adverse Event was any unfavorable and unintended sign, symptom, or disease documented in the medical chart that occurred after treatment with botulinum toxin, or pre-existing conditions that worsened during the retrospective period.
Botulinum Toxin Inter-injection Interval

Time frame: 2 Years

Injection-interval was the time in weeks between injections of botulinum toxin.

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start: 2013
Primary completion: 2013
Study completion: 2013
First posted: Mar 20, 2013
Registry last updated: Jul 3, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed